Bayer's Sunharbo Approved by FDA for Stroke Risk Reduction

The U.S. FDA has approved Bayer's new blood-thinning drug, Sunharbo, to reduce stroke risk in certain adults. This marks the first U.S. approval for a 'Factor XIa' inhibitor, representing a new class of medicines for stroke prevention. A large study showed a 26% reduction in ischemic stroke risk with similar major bleeding rates, offering a significant new treatment option.